U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06951971) titled 'Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis' on April 23.
Brief Summary: This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Hemophagocytic Lymphohistiocytosis (HLH)
Intervention:
DRUG: dose-modified E-Ru
Emapalumab (1-2 mg/kg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)
OTHER: Salvage treatment and follow-up
1) for patients who did not...